Table 2.
Long-term treatment efficacy of peginterferon treatment in hepatitis B e antigen-positive chronic hepatitis B
| Ref. | No. of patients | Formula of therapy | Seroconversion from HBeAg to anti-HBe (%) | Suppression of HBV DNA (%) | Normalization of ALT (%) | HBsAg loss (n) |
| cBuster et al[31] | 91 | Peg-IFNα-2b for 52 wk | 35 | 25a | 30 | 7 (8%) |
| 81 | Peg-IFNα-2b plus LAM for 52 wk | 25 | 31a | 30 | 12 (15%) | |
| dWong et al[32] | 85 | Peg-IFNα-2b for 32 wk plus LAM for 52 or 104 wk | 60 | 13b | 57 | 2 (2.4%) |
a < 10000 copies/mL; b < 100 copies/mL. The treatment efficacies were assessed at approximately 3-year follow-upc or approximately 5-year follow-upd. LAM: Lamivudine; Peg-IFN: Peginterferon; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase.